Pharma Stocks with High DII Holding

The table below shows the pharma stocks with high DII holdings based on the highest market capitalization.

What Are The Pharma Stocks with High DII Holding?

Pharma stocks with high Domestic Institutional Investor (DII) holding refer to shares of pharmaceutical companies where a significant percentage of the stock is owned by domestic financial institutions. High DII holding often signifies robust domestic confidence in the company’s growth prospects, financial stability, and long-term potential in the pharmaceutical sector, potentially leading to increased stock value and market credibility.

Features Of Top Pharma Stocks with High DII Holding

The feature of top pharma stocks with high DII holding includes strong domestic confidence in their growth potential and stability, as evidenced by substantial investment from domestic institutions.

1. Solid Financial Performance: Companies consistently demonstrate robust revenue growth and profitability, attracting substantial domestic investment.
2. Innovative R&D: High DII holding firms invest heavily in research and development, leading to a strong pipeline of new drugs and therapies.
3. Regulatory Compliance: These companies maintain high standards of regulatory compliance, ensuring market trust and operational sustainability.
4. Market Leadership: Often, these firms hold leading positions in their market segments, showcasing strong competitive advantages and strategic positioning.
5. Strong Governance: High DII holding is associated with firms that exhibit excellent corporate governance practices, enhancing transparency and investor confidence.

Best Pharma Stocks with High DII Holding

The table below shows the best pharma stocks with high DII holding based on the highest day Volume.

Top Pharma Stocks with High DII Holding in India

The table below shows the top pharma stocks with high DII holding in India based on 1-Year Return. 

Factors To Consider When Investing In Pharma Stocks with High DII Holding

The factor to consider when investing in pharma stocks with high DII holdings is the stability these investments bring due to the involvement of institutional investors.

1. Growth Potential: Assess the company’s pipeline for new drugs and therapies, which can drive future revenue and profit growth.
2. Financial Health: Examine the company’s balance sheet, profitability, and cash flow to ensure financial stability.
3. Regulatory Environment: Understand the impact of regulatory approvals and compliance on the company’s operations and profitability.
4. Market Position: Evaluate the company’s market share, competitive edge, and brand reputation in the pharmaceutical industry.
5. Innovation and R&D: Look into the company’s investment in research and development, a key driver of long-term success in the pharma sector.

How To Invest In Pharma Stocks with High DII Holding?

To invest in pharma stocks with high DII holdings, open a trading account with a brokerage such as Alice Blue here. Research potential stocks, focusing on their financial health, growth potential, and market position. Stay informed about industry trends and regulatory changes. Diversify your investments to manage risks effectively, and consider consulting a financial advisor for personalized guidance.

Advantages Of Investing In Pharma Stocks with High DII Holding

The primary advantage of investing in pharma stocks with high DII holding is the potential for stable returns due to institutional investors’ extensive research and long-term perspectives.

1. Expert Analysis: Benefit from the thorough research and analysis performed by institutional investors.
2. Stability: Enjoy potential stability and reduced volatility due to significant institutional ownership.
3. Growth Potential: Gain from the growth prospects of companies heavily backed by knowledgeable investors.
4. Market Confidence: Higher DII holdings often reflect strong market confidence in the company’s future.
5. Long-term Focus: Institutional investors usually have a long-term investment horizon, aligning with sustainable growth.

Risks Of Investing In Pharma Stocks with High DII Holding

The main risk of investing in pharma stocks with high DII holding is the potential for sudden market reactions to regulatory changes or clinical trial outcomes, leading to significant stock price volatility.

1. Regulatory Risks: Changes in regulations can negatively impact stock performance.
2. Clinical Trials: Unsuccessful clinical trials can lead to substantial financial losses.
3. Market Sentiment: Stocks can be affected by overall market sentiment, causing volatility.
4. Dependency: High dependence on a few key products can be risky if those products face issues.
5. Exit Strategy: Large institutional investors may sell off shares, leading to sudden price drops.

Introduction to Pharma Stocks with High DII Holding 

Ami Organics Ltd

The Market Cap of Ami Organics Ltd is Rs. 8,557.55 crore. The stock’s monthly return is 0.82%. Its one-year return is 80.11%. The stock is 10.99% away from its 52-week high.

Ami Organics Ltd is a specialty chemicals company based in India. The company focuses on the production of advanced pharmaceutical intermediates and specialty chemicals, which are used in a wide variety of industries including pharmaceuticals, agrochemicals, and fine chemicals. Ami Organics has carved a niche for itself by developing innovative, high-value products for global markets. With a strong emphasis on research and development, the company continually evolves its product portfolio to meet the changing demands of the industries it serves.

The company is recognized for its commitment to sustainability, utilizing environment-friendly processes in its manufacturing units. Ami Organics exports its products to over 25 countries, making it a prominent player in the specialty chemicals industry. Its robust operational capabilities and customer-centric approach have helped the company achieve consistent growth. With its extensive product range, Ami Organics remains a trusted partner for leading global pharmaceutical and specialty chemical companies, ensuring quality and timely delivery.

Gland Pharma Ltd

The Market Cap of Gland Pharma Ltd is Rs. 29,060.56 crore. The stock’s monthly return is -1.48%. Its one-year return is -4.13%. The stock is 25.91% away from its 52-week high.

Gland Pharma Ltd is a Hyderabad-based pharmaceutical company specializing in injectable products. The company has a strong presence in regulated markets, including the United States, Europe, Canada, and Australia. It offers a wide range of products, including generic injectables, specialty injectables, and complex drug delivery systems. Gland Pharma has a reputation for manufacturing high-quality, sterile injectables in compliance with stringent regulatory standards, which has cemented its position as a global leader in this niche.

The company’s focus on research and development enables it to maintain a competitive edge by continuously introducing new and innovative products. Gland Pharma’s vertically integrated operations, from API development to final dosage manufacturing, ensure cost efficiency and supply chain reliability. With strategic partnerships and a diversified product portfolio, the company continues to expand its reach globally while maintaining a strong domestic presence.

Shilpa Medicare Ltd

The Market Cap of Shilpa Medicare Ltd is Rs. 8,120.56 crore. The stock’s monthly return is -5.95%. Its one-year return is 128.13%. The stock is 15.55% away from its 52-week high.

Shilpa Medicare Ltd is an Indian pharmaceutical company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), formulations, and other drug intermediates. The company has a strong focus on oncology and specialty generic drugs, which are its primary growth drivers. With a diversified product portfolio, Shilpa Medicare serves both domestic and international markets, including highly regulated regions like the United States and Europe.

The company has invested heavily in research and development to expand its capabilities in biologics and complex generics. This focus has allowed Shilpa Medicare to cater to emerging opportunities in the pharmaceutical industry, particularly in the high-margin oncology segment. The company also emphasizes sustainability and quality in its operations, adhering to stringent regulatory norms to ensure compliance and customer satisfaction.

Entero Healthcare Solutions Ltd

The Market Cap of Entero Healthcare Solutions Ltd is Rs. 6,390.54 crore. The stock’s monthly return is 6.54%. Its one-year return is 27.82%. The stock is 7.82% away from its 52-week high.

Entero Healthcare Solutions Ltd is a healthcare company specializing in the distribution of pharmaceutical products. It acts as a bridge between pharmaceutical manufacturers and retailers, ensuring efficient supply chain management. Entero Healthcare’s strong network and operational efficiency enable it to cater to a wide range of customers, including hospitals, pharmacies, and other healthcare providers.

The company’s emphasis on technology-driven solutions has streamlined its operations, enhancing its ability to meet the growing demand for healthcare products. By maintaining a robust distribution network and investing in advanced logistics, Entero Healthcare has become a trusted partner for leading pharmaceutical companies. Its focus on innovation and customer satisfaction drives its consistent growth in the healthcare industry.

Wockhardt Ltd

The Market Cap of Wockhardt Ltd is Rs. 23,491.06 crore. The stock’s monthly return is 26.24%. Its one-year return is 244.87%. The stock is 6.28% away from its 52-week high.

Wockhardt Ltd is an Indian multinational pharmaceutical and biotechnology company. The company is known for its focus on research and development, particularly in the fields of biosimilars, new chemical entities (NCEs), and generic drugs. Wockhardt has a strong presence in regulated markets, including the United States and Europe, where it offers a wide range of products in segments such as anti-infectives, cardiovascular, and diabetes.

With its state-of-the-art manufacturing facilities and a robust pipeline of innovative products, Wockhardt continues to address unmet medical needs globally. The company is committed to improving healthcare outcomes through the development of affordable and high-quality medicines. Wockhardt’s emphasis on innovation and global expansion ensures its continued success in the pharmaceutical industry.

Granules India Ltd

The Market Cap of Granules India Ltd is Rs. 14,472.02 crore. The stock’s monthly return is 10.06%. Its one-year return is 48.35%. The stock is 20.81% away from its 52-week high.

Granules India Ltd is a leading pharmaceutical company engaged in manufacturing and distributing active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages. The company operates state-of-the-art manufacturing facilities with a strong focus on operational efficiency and cost competitiveness. Its products are exported to over 75 countries, including the United States and European Union, making it a global player in the pharmaceutical industry.

Granules India has built a reputation for reliability and quality, supplying essential drugs like Paracetamol, Ibuprofen, and Metformin to some of the world’s largest pharmaceutical companies. The company’s strategic emphasis on backward integration and large-scale production ensures cost efficiency, which has driven its consistent growth in revenues and profitability. With a growing portfolio and focus on R&D, Granules India aims to expand its reach further into complex generics and value-added formulations.

Alkem Laboratories Ltd

The Market Cap of Alkem Laboratories Ltd is Rs. 65,680.04 crore. The stock’s monthly return is -3.62%. Its one-year return is 12.03%. The stock is 17.23% away from its 52-week high.

Alkem Laboratories Ltd is one of India’s leading pharmaceutical companies, primarily focused on branded generics, generic drugs, and over-the-counter (OTC) products. With a robust presence in India and a growing footprint in international markets like the United States and European Union, Alkem is a trusted name in healthcare. Its extensive portfolio covers therapeutic segments such as anti-infectives, gastrointestinal, and cardiovascular drugs.

Alkem’s investments in research and development have enabled the company to launch several innovative drugs and secure approvals for complex generics in regulated markets. The company’s vertically integrated operations, encompassing API manufacturing and finished formulations, ensure quality and cost efficiency. Alkem’s focus on expanding its international footprint and diversifying its product offerings positions it well for sustained growth in the pharmaceutical sector.

Amrutanjan Health Care Ltd

The Market Cap of Amrutanjan Health Care Ltd is Rs. 2,171.11 crore. The stock’s monthly return is 6.45%. Its one-year return is 26.48%. The stock is 14.81% away from its 52-week high.

Amrutanjan Health Care Ltd is a well-known consumer healthcare company in India, offering a wide range of products in pain management, personal hygiene, and healthcare. The company’s flagship product, Amrutanjan Pain Balm, has been a household name for decades, known for its effective relief from headaches and body aches. Amrutanjan’s portfolio has expanded to include roll-ons, sprays, and health drinks catering to evolving consumer needs.

With a strong distribution network and brand recognition, the company has maintained a leading position in the market. Amrutanjan is also investing in new product lines and innovative marketing strategies to attract a younger demographic. Its commitment to sustainability and quality ensures that it remains a trusted name in Indian households while exploring growth opportunities in international markets.

Dr Reddy’s Laboratories Ltd

The Market Cap of Dr Reddy’s Laboratories Ltd is Rs. 1,06,250.04 crore. The stock’s monthly return is 3.46%. Its one-year return is 14.06%. The stock is 11.45% away from its 52-week high.

Dr Reddy’s Laboratories Ltd is a global pharmaceutical company based in India, offering a diverse portfolio of generic drugs, branded formulations, and biosimilars. With operations in over 25 countries, including a strong presence in the United States and Europe, Dr Reddy’s is recognized for its focus on affordability and innovation in healthcare. The company caters to therapeutic areas such as oncology, gastroenterology, and dermatology.

Dr Reddy’s investment in research and development has led to significant advancements in drug discovery and the launch of several biosimilars. The company also focuses on improving healthcare access through affordable medications and sustainability initiatives. With a robust pipeline and operational excellence, Dr Reddy’s Laboratories continues to address global healthcare challenges effectively.

Eris Lifesciences Ltd

The Market Cap of Eris Lifesciences Ltd is Rs. 18,912.44 crore. The stock’s monthly return is 4.61%. Its one-year return is 57.80%. The stock is 14.73% away from its 52-week high.

Eris Lifesciences Ltd is a specialty pharmaceutical company focusing on branded formulations in India. The company primarily targets chronic and lifestyle-related therapeutic areas such as diabetes, cardiovascular diseases, and gastrointestinal disorders. With a strong emphasis on doctor-centric marketing, Eris has built a reputation for high-quality, effective medications tailored to Indian healthcare needs.

Eris’s strategy includes partnerships with global players to introduce innovative drugs in the Indian market. The company’s robust financials and operational efficiencies have driven consistent growth. By focusing on specialty segments and leveraging its strong distribution network, Eris Lifesciences is well-positioned to maintain its leadership in the Indian pharmaceutical sector.

Top Pharma Stocks with High DII Holding – FAQs

We hope you’re clear on the topic, but there’s more to explore in stocks, commodities, mutual funds, and related areas. Here are important topics to learn about.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.